Candidal Vulvovaginitis
Candidal Vulvovaginitis, also known as a Yeast Infection or Vulvovaginal Candidiasis, is a common fungal infection. This page provides information for healthcare professionals on diagnosis, treatment, and clinical documentation of Candidal Vulvovaginitis, including relevant medical coding terms for accurate billing and record keeping. Learn about symptoms, diagnostic criteria, and best practices for managing this condition in a clinical setting.
Fungal infection of the vulva and vagina caused by Candida species, typically Candida albicans.
Itching, burning, redness, swelling, thick white discharge, painful urination, and dyspareunia.
Outpatient clinics, telehealth consultations, primary care, gynecology, and sexual health clinics.
ICD-10 Code Families
Complete code families applicable to B37.3
When to use each related code
| Description | When to use |
|---|---|
| Yeast infection of the vulva and vagina. | Vulvovaginal itching, burning, discharge. Consider in women with diabetes or recent antibiotic use. |
| Bacterial vaginosis, not candida. | Vaginal discharge with fishy odor, clue cells on microscopy. Not itchy or painful typically. |
| Inflammation of the vagina, not from infection. | Vaginal irritation, often related to irritants or hormonal changes. No infectious agent found. |
Best-practice checklist
- ✓Document pruritus, burning, or irritation.
- ✓Describe discharge if present (e.g., thick, white, cottage cheese-like).
- ✓Note erythema, edema, or excoriations of vulva.
- ✓Record patient-reported symptoms and duration.
- ✓Confirm diagnosis with KOH prep or culture if needed.
Common pitfalls to avoid
Coding for unspecified candidiasis (B37.9) when clinical details support a more specific code like B37.3 (Candidal vulvovaginitis).
Coding candidal vulvovaginitis based on symptoms alone without confirmatory diagnostic testing, leading to potential overcoding and inaccurate data.
Failing to capture and code related conditions like diabetes, which can predispose to candidal vulvovaginitis, impacting risk adjustment and quality metrics.
Best-practice tips
- 01Improve CDI: Document yeast species for accurate Rx.
- 02Medical Coding: Use ICD-10 B37.3 for candidal vulvovaginitis.
- 03Compliance: Stress hand hygiene to prevent spread.
- 04Coding/CDI: Note if infection is recurrent or complicated.
- 05Best practice: Avoid douching to maintain vaginal flora.
Step-by-step checklist
- 1
Confirm thick, white discharge (cottage cheese-like)
- 2
Verify vulvar/vaginal itching, burning, or redness
- 3
Check for normal pH (<4.5) to exclude BV/Trich
- 4
Consider wet mount microscopy for Candida visualization
Ready-to-paste narrative
Patient presents with complaints consistent with vulvovaginal candidiasis, also known as a yeast infection or candidal vulvovaginitis. Symptoms include vulvar pruritus, burning, and thick, white, cottage cheese-like vaginal discharge. Patient reports no fever or chills. Erythema and edema of the vulva and vagina were noted upon examination. A wet mount preparation revealed pseudohyphae and budding yeast, confirming the diagnosis of candidal vulvovaginitis. Differential diagnoses considered included bacterial vaginosis and trichomoniasis. Patient denies recent antibiotic use or other predisposing factors. Treatment plan includes fluconazole 150mg PO single dose. Patient education provided on proper hygiene practices and preventative measures for recurrent yeast infections. Follow-up recommended if symptoms do not resolve within one week. ICD-10 code B37.3 assigned.
Common questions and answers
What are the most effective diagnostic approaches for recurrent vulvovaginal candidiasis in non-pregnant patients, considering both clinical presentation and laboratory confirmation?+
Recurrent vulvovaginal candidiasis (RVVC), defined as four or more episodes per year, presents a diagnostic challenge. Clinical presentation alone isn't sufficient due to overlapping symptoms with other vulvovaginal conditions. While vaginal pH and wet mount microscopy with potassium hydroxide (KOH) are commonly used, their sensitivity for non-albicans species is limited. Culture on Sabouraud's dextrose agar remains the gold standard for species identification, crucial for targeted therapy and management of RVVC. Molecular methods, such as PCR, offer increased sensitivity and specificity, especially for detecting non-albicans species and mixed infections. A comprehensive approach, considering both clinical signs and symptoms alongside confirmatory laboratory tests, is vital for accurately diagnosing RVVC. Explore how antifungal susceptibility testing can further personalize treatment strategies for recurrent infections.
How do I differentiate vulvovaginal candidiasis from bacterial vaginosis and other common vaginal infections in a clinical setting, and what specific diagnostic tests should be prioritized?+
Differentiating vulvovaginal candidiasis (VVC) from bacterial vaginosis (BV) and other vaginal infections requires a systematic approach. While VVC typically presents with thick, white discharge and pruritus, BV often features a thin, homogenous, grayish discharge with a characteristic fishy odor. Trichomoniasis may present with frothy discharge and vulvar irritation. Microscopic examination with KOH can reveal fungal elements in VVC, while a wet mount for BV may show clue cells and a pH above 4.5. Amsel criteria are helpful for diagnosing BV, while nucleic acid amplification tests (NAATs) are highly sensitive and specific for Trichomonas vaginalis. Consider implementing a diagnostic algorithm that incorporates clinical findings, microscopic evaluation, and point-of-care or laboratory testing for accurate differentiation and appropriate treatment selection. Learn more about the role of vaginal pH and its interpretation in various vaginal infections.
What are the current CDC guidelines for the treatment of uncomplicated and complicated vulvovaginal candidiasis, including recommended antifungal agents, dosages, and duration of therapy for both pregnant and non-pregnant women?+
The CDC recommends short-course antifungal therapy for uncomplicated vulvovaginal candidiasis (VVC) in non-pregnant women. Options include oral fluconazole (150 mg single dose), intravaginal clotrimazole, or other azole antifungals. For pregnant women, only topical azoles are recommended, with longer durations of therapy (7 days). Complicated VVC, including recurrent infections, severe symptoms, or non-albicans species, requires longer durations of oral or topical therapy and may necessitate suppressive maintenance therapy. The choice and duration of antifungal treatment should be individualized based on the patient's clinical presentation and history. Explore how the CDC guidelines address the management of VVC in specific populations, such as those with diabetes or immunocompromised states.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.